Sunday, November 19, 2017
 
 
Company News: Page (1) of 1 - 09/10/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in patients with platinum-refractory advanced urothelia...
(September 10, 2017)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Disease,Surgery,healthcare,medical technologists,Pregnancy,Cancer,Surgery,Medication,Womens Health,Pregnancy,Science,Medical,Biology,Cancer,Other,Women,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines